KRAS induces lung tumorigenesis through microRNAs modulation

Area of Science:

• Molecular Oncology
• Cancer Biology
• Biochemistry

Background:

• Oncogenic KRAS is a key driver in non-small cell lung cancer (NSCLC) pathogenesis.
• MicroRNAs (miRNAs) are critical regulators of gene expression implicated in tumorigenesis.
• Understanding KRAS-mediated miRNA regulation is essential for NSCLC treatment.

Purpose of the Study:

• To investigate the role of KRAS-regulated miRNAs in NSCLC.
• To identify potential diagnostic biomarkers and therapeutic targets for NSCLC.

Main Methods:

• Overexpression of wild type and mutant KRAS (KRAS^G12D) in human and mouse cell lines.
• Analysis of miRNA expression profiles in NSCLC cells and patient samples.
• In vivo studies using a mouse model of lung cancer and systemic delivery of anti-miRNA oligonucleotides.
• Mechanistic studies involving transcription factor binding assays.

Main Results:

• KRAS isoforms upregulate miR-30c and miR-21, which inhibit tumor suppressor genes (NF1, RASA1, BID, RASSF8), enhancing drug resistance and cell migration/invasion.
• Elevated miR-30c and miR-21 levels were observed in early-stage NSCLC tumors and plasma compared to normal lung tissue.
• Systemic delivery of LNA-anti-miR-21 combined with cisplatin suppressed lung tumor development in mice.
• ELK1 was identified as a transcriptional activator of miR-30c and miR-21.

Conclusions:

• miR-30c and miR-21 are oncogenic drivers in NSCLC, acting as potential biomarkers for early detection.
• Targeting miR-30c and miR-21 through silencing offers a promising therapeutic strategy for NSCLC.